View:
PULSE BIOSCIENCES, INC.
957 Point Eden Way
Hayward, California 94545
May 7, 2020
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549-3561
|
Attention:
|
Mr. Jeffrey Gabor
|
|
Ms. Celeste Murphy
|
|
|
Re:
|
Pulse Biosciences, Inc.
|
|
Registration Statement on Form S-3
|
|
|
Filed April 6, 2020
|
|
|
File No. 333-237577
|
|
|
Acceleration Request
|
|
|
Requested Date: May 8, 2020
|
|
|
Requested Time: 4:00 p.m. Eastern Time
|
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Company”) hereby requests that the
above-referenced Registration Statement on Form S-3, as amended (File No. 333-237577) (the “Registration Statement”), be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such
later time as the Company may request by telephone to the staff of the Securities and Exchange Commission.
The Company hereby authorizes Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, P.C., counsel for the Company, to make such
request on the Company’s behalf.
The Company requests that it be notified of the effectiveness of the Registration Statement by contacting Andrew D. Hoffman at (650)
849-3240 or ahoffman@wsgr.com.
|
Sincerely,
|
||
|
PULSE BIOSCIENCES, INC.
|
||
|
By:
|
/s/ Sandra A. Gardiner
|
|
|
Sandra A. Gardiner
Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer
|
||
cc: Andrew D. Hoffman, Esq.,
Wilson Sonsini Goodrich & Rosati, P.C.